Table 2.
Clinical characteristics of improved and non-improved groups of the patients with HBV-ACLF before and after the third treatment of ALSS
| Characteristics | Improved-before (n = 12) | Non-improved-before (n = 10) | Improved-After (n = 12) | Non-improved-After (n = 10) | P-before | P-after |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years) | 45.42 ± 15.12 | 46.7 ± 13.71 | 45.42 ± 15.12 | 46.7 ± 13.71 | 0.838 | - |
| Sex (male/female) | 10/2 | 8/2 | 10/2 | 8/2 | 0.840 | - |
| Laboratory data | ||||||
| HB (g/L) | 118.00 ± 21.17 | 125.50 ± 16.27 | 113.17 ± 23.51 | 111.60 ± 10.87 | 0.370 | 0.772 |
| PLT (109/L) | 83.08 ± 29.54 | 116.40 ± 45.45 | 70.08 ± 30.20 | 66.20 ± 23.42 | 0.051 | 1.000 |
| TP (g/L) | 55.21 ± 5.90 | 55.81 ± 5.11 | 54.83 ± 5.25 | 53.80 ± 5.03 | 0.806 | 0.539 |
| ALB (g/L) | 29.63 ± 2.75 | 31.25 ± 2.68 | 31.98 ± 4.69 | 32.43 ± 2.95 | 0.180 | 0.497 |
| ALT (U/L) | 154.28 ± 182.54 | 475.80 ± 383.12 | 58.17 ± 31.46 | 67.00 ± 39.31 | 0.018 | 0.674 |
| AST (U/L) | 89.25 ± 44.70 | 198 ± 149.12 | 51.67 ± 24.91 | 56.20 ± 35.97 | 0.073 | 0.974 |
| TB (μmol/L) | 355.75 ± 105.69 | 335.28 ± 103.54 | 167.75 ± 74.70 | 282.95 ± 106.44 | 0.653 | 0.003 |
| DB (μmol/L) | 249.63 ± 88.34 | 242.00 ± 88.63 | 131.55 ± 54.11 | 184.10 ± 53.29 | 0.843 | 0.025 |
| Cr (μmol/L) | 65.75 ± 22.76 | 63.70 ± 21.41 | 61.58 ± 15.48 | 59.90 ± 17.02 | 0.831 | 0.628 |
| GFR (mL/min) | 109.00 ± 22.77 | 108.43 ± 18.72 | 113.07 ± 16.90 | 111.28 ± 18.84 | 0.950 | 0.923 |
| UA (μmol/L) | 143.75 ± 70.90 | 110.30 ± 40.27 | 133.25 ± 35.81 | 116.00 ± 43.83 | 0.201 | 0.203 |
| INR | 1.89 ± 0.33 | 2.59 ± 0.66 | 1.70 ± 0.27 | 2.31 ± 0.63 | 0.010 | 0.011 |
| PT (s) | 20.76 ± 3.21 | 27.65 ± 7.36 | 19.18 ± 2.96 | 25.59 ± 7.08 | 0.018 | 0.021 |
| AFP (ng/mL) | 228.45 ± 224.14 | 210.60 ± 318.02 | - | - | 0.881 | - |
| LA (mmol/l) | 2.52 ± 0.47 | 3.29 ± 0.88 | 1.6 ± 0.22 | 2.74 ± 0.55 | 0.028 | < 0.001 |
| Score | ||||||
| MELD | 25.08 ± 2.90 | 28.80 ± 2.89 | 20.75 ± 2.95 | 26.00 ± 3.97 | 0.007 | 0.003 |
| AARC | 8.83 ± 1.26 | 10.10 ± 1.28 | 6.42 ± 0.66 | 9.80 ± 2.09 | 0.032 | < 0.001 |
| HBV-DNA | 1.50*107 ± 1.32*107 | 3.03*107 ± 1.72*107 | 6.78*106 ± 6.48*106 | 2.56*107 ± 1.64*107 | 0.485 | 0.283 |
| ACLF grade | ||||||
| I/II/III | 1/10/1 | 0/7/3 | 12/0/0 | 0/6/4 | 0.306 | < 0.001 |
Data are shown as means ± SDs or number of patients (percentages)
MELD Model for End-Stage Liver Disease, HBV-ACLF Hepatitis B liver failure-related acute-on-chronic liver failure, Sex Sexuality, HB Hemoglobin, PLT Platelet, TP Total protein, ALB Albumin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, TB Total bilirubin, DB Direct bilirubin, Cr Creatinine, GFR Glomerular filtration rate, UA Uric acid, INR International normalized ratio, PT Prothrombin time, AFP Alpha-fetoprotein, LA Lactic acid, AARC ACLF Research Consortium score
*Multiply